Your browser doesn't support javascript.
loading
Effect of Denosumab or Alendronate on Vascular Calcification: Secondary Analysis of SALTIRE2 Randomized Controlled Trial.
Geers, Jolien; Bing, Rong; Pawade, Tania A; Doris, Mhairi K; Daghem, Marwa; Fletcher, Alexander J; White, Audrey C; Forsyth, Laura; Evans, Emily; Kwiecinski, Jacek; Williams, Michelle C; van Beek, Edwin J R; Kwak, Soongu; Peeters, Frederique E C M; Tzolos, Evangelos; Slomka, Piotr J; Lucatelli, Christophe; Ralston, Stuart H; Prendergast, Bernard; Newby, David E; Dweck, Marc R.
Afiliación
  • Geers J; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Bing R; Department of Cardiology Universitair Ziekenhuis Brussel (UZ Brussel) Vrije Universiteit Brussel (VUB) Brussels Belgium.
  • Pawade TA; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Doris MK; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Daghem M; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Fletcher AJ; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • White AC; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Forsyth L; Department of Child Health University of Glasgow Glasgow UK.
  • Evans E; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Kwiecinski J; Edinburgh Clinical Trials Unit University of Edinburgh Edinburgh UK.
  • Williams MC; Edinburgh Clinical Research Facility University of Edinburgh Edinburgh UK.
  • van Beek EJR; Department of Interventional Cardiology and Angiology Institute of Cardiology Warsaw Poland.
  • Kwak S; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Peeters FECM; Edinburgh Imaging University of Edinburgh Edinburgh UK.
  • Tzolos E; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Slomka PJ; Edinburgh Imaging University of Edinburgh Edinburgh UK.
  • Lucatelli C; Department of Internal Medicine Seoul National University Hospital Seoul South Korea.
  • Ralston SH; Maastricht University Medical Centre Maastricht The Netherlands.
  • Prendergast B; BHF Centre for Cardiovascular Science University of Edinburgh Edinburgh UK.
  • Newby DE; Departments of Biomedical Sciences and Medicine Cedars-Sinai Medical Center Biomedical Imaging Research Institute Los Angeles CA USA.
  • Dweck MR; Edinburgh Clinical Research Facility University of Edinburgh Edinburgh UK.
J Am Heart Assoc ; 13(18): e032571, 2024 Sep 17.
Article en En | MEDLINE | ID: mdl-39248270
ABSTRACT

BACKGROUND:

Patients with osteoporosis demonstrate increased vascular calcification but the effect of osteoporosis treatments on vascular calcification remains unclear. The present study aimed to examine whether coronary or aortic calcification are influenced by denosumab and alendronic acid treatment. METHODS AND

RESULTS:

In a double-blind randomized controlled SALTIRE2 (Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis) trial, patients with aortic stenosis were randomized 2121 to denosumab, placebo injection, alendronic acid, or placebo capsule. Participants underwent serial imaging with computed tomography and 18F-sodium fluoride positron emission tomography for the assessment of vascular calcium burden and calcification activity, respectively. We report the prespecified secondary analyses of 24-month change in coronary calcium score, and 12-month changes in thoracic aorta calcium score, coronary and aortic 18F-sodium fluoride activity. One hundred fifty patients with aortic stenosis (72±8 years; 21% female) were randomized to denosumab (n=49), alendronic acid (n=51), and placebo (injection n=25, capsule n=25). There were no differences in change in coronary calcium scores between placebo (16 [-64 to 148] Agatston units) and either denosumab (94 [0-212] Agatston units, P=0.24) or alendronic acid (34 [-62 to 134], P=0.99). There were no differences in change in thoracic aorta calcium scores between placebo (132 [22-512] Agatston units) and either denosumab (118 [11-340], P=0.75) or alendronic acid (116 [26-498] Agatston units, P=0.62). There were no differences in changes in coronary or aortic 18F-sodium fluoride activity between treatment groups.

CONCLUSIONS:

Neither alendronic acid nor denosumab are associated with changes in the activity or progression of coronary or aortic calcification. Osteoporosis treatments do not appear to have major impact on vascular calcification of atherosclerosis. REGISTRATION https//www.clinicaltrials.gov; Unique identifier NCT02132026.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alendronato / Conservadores de la Densidad Ósea / Calcificación Vascular / Denosumab Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Heart Assoc Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alendronato / Conservadores de la Densidad Ósea / Calcificación Vascular / Denosumab Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Heart Assoc Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido